



an Open Access Journal by MDPI

Antiphospholipid Syndrome: From Pathophysiology to Novel Therapeutic Approaches

Guest Editor:

Prof. Dr. Matteo Di Minno
Department of Translational
Medical Sciences, Federico II
University, Naples, Italy

Deadline for manuscript
submissions:
closed (31 May 2021)

Message from the Guest Editor

Dear Colleagues,

The antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by a hypercoagulable state secondary to the presence of antiphospholipid antibodies (aPL), a cluster of autoantibodies directed against plasma proteins that bound membranes phospholipids. In particular, the most frequently found types of aPL are lupus anticoagulant (LA), anticardiolipin antibodies (aCL, IgG and IgM), and anti- β 2-glycoprotein I antibodies (anti- β 2GPI, IgG, and IgM). APS is clinically associated with vascular thromboses (venous, arterial, or small vessel) and/or pregnancy complications (recurrent embryonic or foetal loss, premature birth).

The Special Issue, “Antiphospholipid Syndrome: From Pathophysiology to Novel Therapeutic Approaches”, will focus on the pathophysiological mechanisms, clinical manifestations, and therapeutic approaches of antiphospholipid syndrome.

Dr. Matteo Di Minno

Guest Editor



mdpi.com/si/49096

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)